Top Mefenamic Acid Brand Picks: Your Ultimate Guide

Mefenamic acid is a popular non-steroidal anti-inflammatory drug (NSAID) used for relieving mild to moderate pain, including menstrual pain. With numerous brands available, selecting the right one can make a significant difference in effectiveness and overall experience. It’s essential to consider factors such as dosage, side effects, and user reviews when choosing the ideal brand to suit your needs. Below, we provide a curated list of the best mefenamic acid brands, highlighting their unique features and consumer feedback to guide your decision-making process.

Illustration of mefenamic

Best brands of mefenamic in 2025

Ponstel

Ponstel, a brand of mefenamic acid produced by Pfizer Inc., is a highly effective nonsteroidal anti-inflammatory drug (NSAID) belonging to the fenamate group. It is used to treat pain and inflammation, particularly for conditions like primary spasmodic dysmenorrhea. Each capsule contains 250 mg of mefenamic acid, with a molecular weight of 241.29 and a melting point of 230°-231°C. The global mefenamic acid market, led by North America with over 40% market share, is expected to grow at a CAGR of 5% from 2024 to 2031. Ponstel is available in bottles of 100 capsules and should not be administered to patients with pre-existing renal disease or significantly impaired renal function. For more detailed information, refer to the Ponstel product page.

Meftal

Meftal, produced by Blue Cross Laboratories, is a highly effective brand of mefenamic acid, a non-steroidal anti-inflammatory drug (NSAID) that offers significant relief from mild to moderate pain, including dysmenorrhea and visceral pains. It is rapidly absorbed, with over 90% bound to plasma proteins, and has a biological half-life of approximately two hours. Meftal Spas tablets, which combine mefenamic acid with dicyclomine hydrochloride, are particularly useful for treating abdominal pain and spasms, and are available at an affordable price of around Rs. 50 for a strip of 10 tablets as of 2023. The drug is contraindicated in the last trimester of pregnancy and breastfeeding due to potential side effects. It is also notable for its low incidence of hepatotoxicity, with transient serum aminotransferase elevations seen in less than 5% of patients.

Mefenamic Acid

Mefenamic Acid, particularly the brand from Actavis Pharma, stands out as a leading producer in the global market, which is expected to grow at a compound annual growth rate (CAGR) of 5.00% from 2024 to 2031. North America, where Actavis Pharma operates, holds more than 40% of the global market share, with a CAGR of 3.2% for the region. The drug's effectiveness in pain relief, anti-inflammatory, and antipyretic properties makes it a preferred choice, especially for treating mild to moderate pain and primary dysmenorrhea. Actavis Pharma's product is widely available through retail pharmacies, which hold the largest market share due to their accessibility and trust among consumers. The drug's rapid absorption and high protein binding of 90% contribute to its efficacy. For more detailed information, visit the drug's profile on DrugBank.

Ponstan

Ponstan, a brand by Pfizer Ltd, is a leading producer of mefenamic acid, a non-steroidal anti-inflammatory drug (NSAID) known for its anti-inflammatory, analgesic, and antipyretic properties. It is rapidly absorbed, with peak plasma concentrations achieved within 1-3 hours, and is extensively bound to plasma proteins. Mefenamic acid is indicated for mild to moderate pain in conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhoea, and menorrhagia. The global mefenamic acid market, which includes Ponstan, is expected to grow at a compound annual growth rate (CAGR) of 5% from 2024 to 2031, with North America holding over 40% of the global market share. Nursing mothers are advised against using Ponstan due to the drug's passage into breast milk and potential adverse effects on the child.

Mefac

Mefac, a product from Cipla, is a highly regarded brand for mefenamic acid, a non-steroidal anti-inflammatory drug (NSAID) known for its anti-inflammatory, analgesic, and antipyretic properties. Mefenamic acid is rapidly absorbed from the gastrointestinal tract, with peak plasma levels of 10-20 mg/mL achieved within 2-4 hours, and an elimination half-life of approximately 2 hours. It is extensively bound to plasma proteins, with over 90% binding to albumin, and is metabolized primarily by the CYP2C9 enzyme. The drug is commonly used for treating mild to moderate pain and primary dysmenorrhea, with a typical dosage of 500 mg administered three to four times daily. Mefenamic acid should be used with caution in patients with renal or hepatic impairment due to its significant pathways of elimination through both kidneys and liver.

Dolfenal

Dolfenal, a brand by Myra Pharmaceuticals, is renowned for its high-quality mefenamic acid formulations, which are widely used for relieving mild to moderate pain, including menstrual cramps, dental pain, and musculoskeletal disorders. Mefenamic acid, the active ingredient, works by inhibiting prostaglandin synthesis, providing effective anti-inflammatory, analgesic, and antipyretic effects. The global mefenamic acid market, driven by increasing demand for pain management solutions, is expected to grow at a compound annual growth rate (CAGR) of 5% from 2024 to 2031, with North America holding over 40% of the market share. Dolfenal is available in 250 mg and 500 mg oral capsules, and its efficacy has made it a preferred choice among healthcare providers and patients. The drug is rapidly absorbed, reaching peak plasma concentrations in 2 to 4 hours, and is extensively bound to plasma proteins, ensuring effective and sustained relief.

Mef-250

Mefenamic Acid 250mg Capsules, such as those produced by Sun Pharmaceutical under the brand name Mef-250, are a highly effective non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, and antipyretic properties. Each capsule contains 250mg of mefenamic acid and is commonly used for the relief of mild to moderate pain, including muscular, traumatic, and dental pain, as well as primary dysmenorrhoea and menorrhagia. Mefenamic acid works by inhibiting prostaglandin synthesis, with peak plasma levels attained in 2 to 4 hours and an elimination half-life of approximately 2 hours. It is important to note that mefenamic acid should be used with caution in certain populations, such as pregnant women and those with a history of stomach ulcers or inflammatory bowel disease. The capsules are available in various pack sizes, including 50, 84, 100, 168, and 500 capsules. For more detailed information, you can visit the product's summary of product characteristics.

Fenamic

Mefenamic acid, produced by brands like Fenamic (Micro Labs), is a highly effective nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and primary dysmenorrhea. It is rapidly absorbed after oral administration, with peak plasma levels attained in 2 to 4 hours and an elimination half-life of approximately 2 hours. The drug is metabolized by CYP2C9, with its metabolites undergoing glucuronidation, and it has a high protein binding rate of 90%. Fenamic acid capsules, such as those from Micro Labs, contain 250 mg of mefenamic acid per capsule, ensuring consistent and reliable dosing. This formulation helps in achieving steady-state concentrations quickly, typically by the second day of administration. For more detailed information, you can visit the FDA's DailyMed website.

Novem

Novem, a brand by Somatico Pharmaceuticals, is recognized for its high-quality mefenamic acid formulations, which are widely used to treat pain and inflammation in various conditions, including rheumatoid arthritis, osteoarthritis, and menstrual pain. With a global market share, Novem's mefenamic acid products are known for their efficacy and safety profile, supported by extensive clinical studies. The global mefenamic acid market, which includes Novem's products, is expected to grow at a compound annual growth rate (CAGR) of 5.00% from 2024 to 2031, with North America holding over 40% of the market share. Novem's formulations are designed to enhance bioavailability, addressing the drug's inherent low dissolution rate. The company's commitment to research and development has made it a leading producer in the mefenamic acid market.

Ponmox

Ponmox, a brand by Kopran Ltd, is recognized as a leading producer of mefenamic acid, contributing significantly to the global market. The global mefenamic acid market, which includes brands like Ponmox, is expected to grow at a compound annual growth rate (CAGR) of 5% from 2024 to 2031, with North America holding over 40% of the global revenue. Kopran Ltd's production ensures high-quality mefenamic acid, which is crucial for treating mild to moderate pain and primary dysmenorrhea. The market's positive momentum is driven by advancements in drug formulations and increasing demand. As of 2024, the Asia Pacific region, where Kopran Ltd operates, is expected to see a CAGR of 7% in the mefenamic acid market.